Expression and function of CD95 (FAS/APO-1) in leukaemia-lymphoma tumour lines

被引:62
|
作者
Dirks, W
Schone, S
Uphoff, C
Quentmeier, H
Pradella, S
Drexler, HG
机构
[1] DSMZ-Ger. Collec. Microorganisms C., Braunschweig
[2] DSMZ, D-38124 Braunschweig
关键词
haemopoietic cell lines; CD95 (FAS/APO-1) expression; apoptosis; programmed cell death; cell death resistance;
D O I
10.1046/j.1365-2141.1997.d01-2048.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cross-linkage of the CD95 (FAS/APO-1) antigen is responsible for the induction of programmed cell death or apoptosis in a variety of normal and malignant cells of the haemopoietic system. In order to evaluate predominant expression of the CD95 gene in a cell lineage-specific manner, we have determined the CD95 expression patterns in cell lines of myeloid, T-, pre-B- or B-cell origin as well as those established from Hodgkin's disease (HD). Our results reveal constitutive transcriptional activation of the CD95 gene in all cell lines derived from the lymphoid and myeloid lineages. Despite the ubiquitous expression of CD95 transcripts in haemopoietic cells, the corresponding protein was undetectable in 2/5 cell lines derived from Burkitt lymphomas and 6/16 leukaemia cell lines of the megakaryocytic or monocytic lineage. In an effort to identify apoptosis-resistant cell lines resulting from mutations in the death-signalling domain of CD95 or from defects in the apoptotic pathway or in survival programmes, we applied a CD95-mediated apoptosis assay. However, 21/38 CD95-expressing cell lines were sensitive upon induction with an anti-CD95 antibody whereas the remaining cell lines (predominantly of myeloid derivation) were resistant to antibody-induced cell death, Resistance to CD95-mediated apoptosis was not due to mutations within the CD95 open reading frame as confirmed by a combined reverse transcription PCR sequencing method. Fine myeloid out of 13 tumour lines with the apoptosis-resistance phenotype analysed showed programmed cell death, when protein synthesis was blocked by treatment with cycloheximide prior to CD95-mediated induction. These data suggest an active cellular mechanism for the maintenance of an apoptosis-resistant phenotype, Elucidating the steps in such an active process of resistance to apoptosis might be expected to provide new approaches for therapeutic intervention in certain tumours.
引用
收藏
页码:584 / 593
页数:10
相关论文
共 50 条
  • [31] DIFFERENTIAL EXPRESSION OF APO-1 (FAS/CD95) ON HUMAN HEMATOPOIETIC-CELLS
    STAHNKE, K
    KLEIHAUER, E
    DEBATIN, KM
    EXPERIMENTAL HEMATOLOGY, 1995, 23 (08) : 888 - 888
  • [32] Fas/APO-1 (CD95) expression in peripheral blood of gastric cancer patients
    Jaunalksne, I
    Engele, L
    Januskevics, V
    Donina, S
    Zakenfelds, G
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S13 - S13
  • [33] Sensitivity and resistance to apoptosis in the APO-1 (Fas/CD95) system
    Debatin, KM
    ONKOLOGIE, 1996, 19 : 3 - 5
  • [34] CD95 (APO-1/Fas) and Parkinson's disease - Reply
    Zipp, F
    Martin, R
    Dichgans, J
    Weller, M
    ANNALS OF NEUROLOGY, 1998, 44 (03) : 426 - 426
  • [35] APO-1/Fas(CD95)分子研究进展
    陈俊,郭坤元
    国外医学(免疫学分册), 1996, (02) : 61 - 65
  • [36] Modulation of CD95 (APO-1/Fas)-induced hepatocyte death by NO
    Galle, PR
    Strand, D
    Su, Z
    Theobald, M
    Harris, CC
    Strand, S
    CYTOKINES IN LIVER INJURY AND REPAIR, 2002, 125 : 25 - 30
  • [37] The APO-1 (FAS/CD95)-mediated death-signal
    Krammer, PH
    Hellbardt, S
    Kischkel, F
    Peter, M
    JOURNAL OF BRAIN RESEARCH-JOURNAL FUR HIRNFORSCHUNG, 1996, 37 (04): : 597 - 598
  • [38] Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases
    Nozawa, K
    Kayagaki, N
    Tokano, Y
    Yagita, H
    Okumura, K
    Hasimoto, H
    ARTHRITIS AND RHEUMATISM, 1997, 40 (06): : 1126 - 1129
  • [39] CD95 (Fas/Apo-1)-induced apoptosis results in loss of glucose transporter function
    Berridge, MV
    Tan, AS
    McCoy, KD
    Kansara, M
    Rudert, F
    JOURNAL OF IMMUNOLOGY, 1996, 156 (11): : 4092 - 4099
  • [40] (-)-Epigallocatechin-3-gallate (EGCG) modulates FAS (APO-1/CD95) expression in CTCL derived lines
    Nihal, M.
    Wu, J.
    Wood, G. S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 : 44 - 44